Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 15.4.2019 | EN | Official Journal of the European Union | C 139/51 |

---

Judgment of the General Court of 6 March 2019 — Serenity Pharmaceuticals v EUIPO — Gebro Holding (NOCUVANT)

(Case T-321/18) [(1)](#ntr1-C_2019139EN.01005101-E0001)

(EU trade mark - Opposition proceedings - Application for EU word mark NOCUVANT - Earlier word marks NOCUTIL - Proof of genuine use - Article 47(2) of Regulation (EU) 2017/1001 - Relative ground for refusal - Likelihood of confusion - Similarity of the signs - Article 8(1)(b) of Regulation 2017/1001)

(2019/C 139/51)

Language of the case: English

Parties

Applicant: Serenity Pharmaceuticals LLC (Milford, Pennsylvania, United States) (represented by: J. Day, Solicitor)

Defendant: European Union Intellectual Property Office (represented by: A. Lukošiūtė and H. O’Neill, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Gebro Holding GmbH (Fieberbrunn, Austria) (represented by: M. Konzett, lawyer)

Re:

Action brought against the decision of the Second Board of Appeal of EUIPO of 8 March 2018 (Case R 584/2017-2), relating to opposition proceedings between Gebro Holding and Allergan, Inc.

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Serenity Pharmaceuticals LLC to pay the costs. |

---

---

[Top](#document1)